Preparation and characterization of human anti-trop-2 engineering antibody fab

Progress in Biochemistry and Biophysics

Volumn 37, Issue 10, 2010, Pages 1101-1107

  Lin, Hong ^a   Liang, Jie ^a   Zhang, Hui Lin ^a   Tang, Qi ^a   Su, Yi Ping ^a   Cao, Brian ^c   Zhu, Jin ^a,b   Guan, Xiao Hong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Huadong Medical Institute of Biotechniques   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Human anti Trop 2 antibody fragment Fab; Pancreatic carcinoma; Phage displayed antibody library

Indexed keywords

EID: 79951916826     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2010.00211     Document Type: Article

References (17)

1. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol, 2008, 9(1): 39-44
2. Iacobuzio-Donahue C A, Maitra A, Shen-Ong G L, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol, 2002, 160(4): 1239-1249 (Pubitemid 34411628)
3. Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res, 2007, 13(11): 3356-3362 (Pubitemid 46944923)
4. Gómez-Varela D, Zwick-Wallasch E, Kntgen H, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res, 2007, 67(15): 7343-7349 (Pubitemid 47206564)
5. Ripani E, Sacchetti A, Corda D, et al. Human TROP-2 is a tumor-associated calcium signal transducer. Int J Cancer, 1998, 76: 671-676 (Pubitemid 28243939)
6. Villablanca E J, Renucci A, Sapede D, et al. Control of cell migration in the zebrafish lateral line: implication of the gene 'tumour-associated calcium signal transducer,' tacstd. Dev Dyn, 2006, 235(3): 1578-1588 (Pubitemid 43787960)
7. Guerra E, Trerotola M, Arciprete R D, et al. A bicistronic cyclin D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res, 2008, 68(19): 8113-8121
8. Alberti S, Vacca G, Trerotola M, et al. Trop-2 is a novel PKC-dependent growth-stimulator trans-membrane molecule and a metastasis marker in human cancer. Proc Amer Assoc Cancer Res, 2006, 47: 2483
9. Alberti S, Trerotola M, Vacca G, et al. Novel role of TROP2 in breast cancer growth and metastatization. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I, 2007, 25(18S): 10510
10. Fong D, Spizzo G, Gostner J M, et al. TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathology, 2008, 21(12): 186-191 (Pubitemid 351172170)
11. Nakashima K, Shimada H, Ochiai T. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer, 2004, 112(6): 1029-1035 (Pubitemid 39507010)
12. Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. British J Cancer, 2008, 99(8): 1290-1295
13. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res, 2004, 10(5): 3131-3136 (Pubitemid 38619694)
14. Weiner L M, Carter P. Tunable antibodies. Nature Biotech, 2005, 23(5): 556-557 (Pubitemid 41724893)
15. Leclerc E, Liemann S, Wildegger G, et al. Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum Antibodies, 2000, 9(4): 207-214 (Pubitemid 32245879)
16. Dornh'fer N, Spong S, Bennewith K, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res, 2006, 66 (11): 5816-5827 (Pubitemid 43927136)
17. Kindler H L, Friberg G, Stadler W M, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanc edpancreatic cancer (PC): updated results of a multi-center phase II trial. J Clin Oncol, 2004, 22(14S): 4009